Navigation Links
Evaluating That Thing On Your Skin Just Got a Whole Lot Easier
Date:11/5/2013

BOSTON, Nov. 5, 2013 /PRNewswire/ -- Olay® facial cream's famous motto was "Love the skin you're in." We should, since our largest organ does so much for us. Skin acts as a waterproof insulating shield, guarding the body against extremes of temperature, damaging sunlight and harmful chemicals. It exudes antibacterial substances that prevent infection, and manufactures vitamin D for converting calcium into healthy bones. Skin is also a huge sensor, packed with nerves for keeping the brain in touch with the outside world. But loving the skin we're in is actually easier said than done, because of the ever-present possibility of skin cancer. 

This is an understandable concern, with the American Cancer Society reporting there are more than 3.5 million skin cancers diagnosed each year—more than all other cancers combined. This makes us leery of every suspicious lump, mole, skin tag or discoloration on the body. We also worry that our doctor might overlook a potentially cancerous lesion; or if not, that the biopsy will be painful and leave us with a visible scar. Scarring does happen, even if that suspicious lesion is benign.

Is there an answer to this all-too-prevalent dilemma?

Now there is, thanks to a remarkable advance in medical instrumentation. Based in Boston and Rochester, Caliber Imaging & Diagnostics (Caliber I.D.) is a leader in noninvasive optical biopsies—i.e., its technology can capture high-resolution images providing doctors with cellular views at varying depths under the skin, enabling an accurate real-time diagnosis. Caliber I.D. has created and is already marketing a suite of its FDA-cleared devices, known as VivaScope® confocal imaging systems.

Since there is no cutting involved with VivaScope, there is also no possibility of infection or scarring. Obtaining an image takes just a few minutes so the doctor can make a determination at the bedside, or the image can be transferred within minutes through the company's VivaNet® system, so that a pathologist can diagnose it remotely.

Enthusiastic users include prestigious hospitals and many other leading academic institutions, private physicians' practices and Fortune 500 companies. As CEO L. Michael Hone explains, "The VivaScopes allow physicians to nondestructively examine tissue to determine whether it is responding to therapy; or, when surgery has been performed, to quickly and efficiently examine the skin surrounding the excised cancerous lesion."

Hone adds, "Consult your healthcare provider immediately when you spot anything you think might be questionable. When you see your doctor, you might want to ask if he or she has a VivaScope, the noninvasive way to biopsy your skin."  

For more on this major advance, visit www.caliberid.com, who paid for the writing and dissemination of this release.

Contact: Laura Radocaj, Dian Griesel Int'l., 212.825.3210

 


'/>"/>
SOURCE Caliber I.D.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
2. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
3. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
5. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
6. Study Showcases Effective Approaches for Evaluating the Performance of Executives who Handle Managed Markets Accounts
7. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
8. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
9. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
10. AtheroMed Announces Completion of Patient Enrollment in the EASE Study Evaluating the Phoenix Atherectomy System in Treating PAD
11. AtheroMed Announces Results Of The EASE Study Evaluating The Phoenix Atherectomy System In Treating Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... 8, 2017 ... Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th .The ... free MRI brain scans to the public.Where:  BTF,s ... at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the ...
(Date:9/7/2017)... INDIANAPOLIS , Sept. 7, 2017  Eli ... today announced actions to streamline operations to more ... to improve its cost structure. Global workforce reductions, ... program, are expected to impact approximately 3,500 positions. ... the company expects annualized savings of approximately $500 ...
(Date:9/7/2017)... STOCKHOLM , Sept. 7, 2017 NuvoAir ... Air Smart Spirometer, announced today a partnership with Novartis Pharma ... partnership solidifies NuvoAir,s position as the leading mobile spirometry platform ... respiratory patients. ... spirometry test ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... Driving Dynamics Inc., announced ... Company by Training Industry Inc. as part of its mission to continually monitor the ... to the first annual 2017 Top 20 Health and Safety Training Companies list was ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... the success of the annual PAINWeek National Conference. On October 7, at the ... an educational and exciting program providing busy clinicians and allied healthcare practitioners with ...
(Date:9/19/2017)... ... September 19, 2017 , ... Spain’s popular ... ACPG Laboratories, is coming soon to RonnieColemanNutrition.com. , ACPG Laboratories has been ... a trusted, well-respected brand reliant on the healing properties of plants, a proven ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone Solutions Inc. (BSI), ... magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist ... incorporate magnesium, a critical property for bone health and development. , “We’re excited ...
(Date:9/19/2017)... ... September 19, 2017 , ... For decades doctors, nurses, and ... attack by measuring their risk factors and calculating their cardiovascular disease (CVD) risk in ... the same way CVD is predicted today: an estimated 10-year risk prediction! , Imagine ...
Breaking Medicine News(10 mins):